Offering true paradigm-shifting potential, Vical's efforts are shaping the future of vaccines and gene therapies, and delivering on the promise of novel preventive and therapeutic alternatives for serious and life-threatening diseases.

Vical's core technology grew out of a chance discovery and provided the cornerstones for two new biopharmaceutical industry sectors: DNA vaccines and non-viral gene therapy. 

Vical's management systematically leveraged that technology into a broad portfolio of independent and partnered product development programs. The first products for animal health are on the market. The first human products are approaching.